Welcome to our dedicated page for CollPlant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CollPlant Biotechnologies Ltd. filings document foreign private issuer current reports for a regenerative and aesthetic medicine company built around plant-derived rhCollagen. Form 6-K reports cover operating and financial results, corporate updates on BioInk, Collink.3D, BioFlex, Vergenix STR and photocurable dermal filler technology, as well as intellectual-property disclosures and collaboration-related material events.
The filing record also documents capital-structure matters involving ordinary shares and warrants, Nasdaq Capital Market bid-price compliance notices, and material agreements. Certain 6-K reports are incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, linking current-event disclosures to equity compensation and shelf-registration records.
CollPlant Biotechnologies Ltd (CLGN) received a significant investment from The Loewenbaum 1992 Trust, which on June 29, 2026 agreed to purchase 1,764,706 Ordinary Shares, Series A Warrants to buy 1,764,706 shares and Series B Warrants to buy 3,529,412 shares at an exercise price of $0.34 per share. The transaction closed on July 6, 2026, with the Series A and B Warrants becoming exercisable following shareholder approval on July 29, 2026, and expiring in 2028 and 2031, respectively.
As of August 19, 2026, CollPlant had 18,908,207 Ordinary Shares outstanding. For ownership calculations, 20,570,548 shares are assumed outstanding, including up to approximately 1,662,341 shares issuable upon warrant exercise subject to a 24.99% Beneficial Ownership Limitation. Collectively, the Loewenbaum-related reporting persons beneficially own 5,140,580 Ordinary Shares, representing 24.99% of this adjusted total. The group states the holdings are for investment purposes and that they currently have no specific plans for corporate actions beyond what is described.
CollPlant Biotechnologies Ltd. (CLGN) reports that it held an Extraordinary General Meeting of Shareholders on August 18, 2026. Shareholders approved both proposals presented at the meeting, each receiving the required majority as outlined in the previously distributed meeting notice.
The report is also incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements, meaning the meeting outcome and related disclosures become part of those registration frameworks.
CollPlant Biotechnologies Ltd. reports that its shareholders have approved an increase in authorized share capital from 30,000,000 to 500,000,000 ordinary shares, each with a par value of NIS 1.50, together with an amendment to its Amended and Restated Memorandum and Articles of Association.
Following this approval, the company has filed an updated opinion from Goldfarb Gross Seligman & Co. on the validity of ordinary shares registered for resale under its Registration Statement on Form F-3 (File No. 333-297347), and this report and its exhibits are incorporated by reference into that registration statement.
A group of investors led by the Loewenbaum family reports a large ownership position in CollPlant Biotechnologies Ltd1,764,706 Ordinary Shares plus Series A Warrants for 1,764,706 shares and Series B Warrants for 3,529,412 shares. The deal closed on July 6, 2026. Both warrant series carry a $0.34 exercise price, are exercisable from July 29, 2026, and expire in 2028 and 2031, respectively, subject to a 24.99% Beneficial Ownership Limitation on exercises by The Loewenbaum 1992 Trust.
As of July 29, 2026, CollPlant had 18,908,207 Ordinary Shares outstanding. For ownership calculations, 22,628,318 shares are assumed, including approximately 3,720,111 shares issuable under the warrants within 60 days. On this basis, the Reporting Persons collectively beneficially own 7,473,536 Ordinary Shares, or 33.0% of the company, with The Loewenbaum 1992 Trust accounting for 5,654,817 shares (25.0%). The stake is held for investment purposes, with no specific corporate actions currently planned.
CollPlant Biotechnologies Ltd. reported that it held an Extraordinary General Meeting of Shareholders on July 29, 2026. Shareholders approved the proposal presented at the meeting, which had been described in the company’s Notice of Extraordinary General Meeting of Shareholders dated July 7, 2026.
The report is incorporated by reference into CollPlant’s existing Registration Statements on Form S-8 and Form F-3, becoming part of those registration statements from the submission date, unless later superseded.
CollPlant Biotechnologies Ltd. is convening an extraordinary general meeting on August 18, 2026 to seek shareholder approval for a reverse split of its ordinary shares at a ratio between 1‑for‑8 and 1‑for‑12, and for eliminating the par value of its share capital.
The board states the reverse split is intended to help address Nasdaq’s Minimum Bid Price Requirement after a notice on March 23, 2026 that the shares had closed below $1.00 for 30 consecutive business days; the last reported closing price on July 27, 2026 was $0.319. If implemented, the reverse split would proportionally adjust outstanding options, restricted share units and warrants and is described as not changing each shareholder’s percentage ownership or voting rights, aside from rounding of fractional shares. As of July 27, 2026 there were 18,908,207 ordinary shares outstanding, excluding 18,409 held in treasury.
CollPlant Biotechnologies Ltd received an ownership update as a Loewenbaum-led group and related entities reported a combined beneficial holding of 3,518,237 Ordinary Shares, representing 18.6% of the company’s 18,908,207 outstanding Ordinary Shares as of March 31, 2026.
On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with CollPlant for 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 shares, and Series B Warrants to purchase 3,529,412 shares, a transaction completed on July 6, 2026. Both warrant series have an exercise price of $0.34 per share and become exercisable only after shareholder approval expected on or about July 29, 2026; the Series A Warrants expire July 16, 2028 and the Series B Warrants expire July 16, 2031. The 18.6% figure includes shares potentially issuable within 60 days under existing options and warrants, but excludes shares underlying these new Warrants until they become exercisable.
CollPlant Biotechnologies Ltd conducted an exempt private securities offering under Rule 506(b) of Regulation D. The notice reports a total amount sold of $10,400,000, including the exercise price of ordinary shares underlying warrants with an exercise price of $0.34, with no remaining amount offered.
The securities consist of equity, Series A and Series B warrants to purchase ordinary shares, and the underlying ordinary shares issuable upon exercise. H.C. Wainwright & Co., LLC acted as placement agent and received fees, expense reimbursements, and placement agent warrants. CollPlant intends to use net proceeds for general corporate purposes, including working capital, R&D programs, and evaluating strategic business combinations and other strategic transactions.
CollPlant Biotechnologies Ltd. is registering for resale by existing investors up to 31,047,068 ordinary shares. These comprise 4,464,707 PIPE Shares and 26,582,361 shares issuable upon exercise of pre-funded, Series A, Series B and placement agent warrants issued in a June–July 2026 private placement.
The company will not receive proceeds from Selling Shareholders’ resales but may receive up to $8.0 million in gross proceeds if all warrants are exercised for cash, to be used for general corporate purposes, working capital, R&D and evaluating strategic combinations. As of March 31, 2026, 14,443,500 shares were outstanding, increasing to 18,908,207 on an as-adjusted basis after the PIPE, which generated approximately $2.3 million in net proceeds.
CollPlant develops rhCollagen-based products for regenerative and aesthetic medicine, including dermal fillers and 3D-bioprinted breast implants. The company reports ongoing losses, negative operating cash flows, and states its current cash resources are not sufficient for the next 12 months, raising substantial doubt about its ability to continue as a going concern absent additional financing.